our products
our products
information_top

Call us at:

(818)591-3030

USA

Click here to send us an email
tel_section

Diagnostic Automation Question & AnswerDiagnostic Automation Question & Answer Diagnostic Automation Articles Diagnostic Automation videos



EBV-EA-D IgM ELISA Kit

Name

EBV-EA-D IgM ELISA Test Kit

Category Name Infectious Disease ELISA kits
Test 96
Method Enzyme linked Immunosorbent Assay
Principle Antigen Coated Plate
Detection Range Qualitative
Sample 10 uL
Specificity N/A
Sensitivity N/A
Total Time 75 min
Shelf Life 12 Months from the manufacturing date

Item #:                    1418-16   Quantity:               

EBV-EA-D IgM ELISA Kit


EBV-EA-D IgM ELISA Kit

callback phone number email us


EBV-EA-D IgM ELISA Kit description:




The Diagnostic Automation,Inc. Epstein Barr Virus Early Antigen (EBV-EA-D) IgM Enzyme-linked Immunosorbent Assay (ELISA), is intended for the detection of IgM antibody to Epstein Barr Virus Nuclear Antigen-1 in human sera and plasma.

Detection of the Epstein-Barr virus was first described in 1964 by Epstein, Achong, and Barr using electron microscopic studies of cultured lymphoblasts derived from patients with Burkitt’s lymphoma1. EBV is classified as a member of the herpes-virus family based upon it’s characteristic morphology2,3.

EBV infection may demonstrate a wide spectrum of clinical symptoms. The majority of primary EBV infections are transmitted via saliva, occur during childhood, and are subclinical. Antibody titers to specific EBV antigens correlate with different stages of IM. Both IgM and IgG antibodies to the viral capsid antigen (VCA) peak 3 to 4 weeks after primary EBV infection. IgM anti-VCA declines rapidly and is usually undetectable after 12 weeks. IgG anti-VCA titers decline slowly after peaking but last indefinitely. Antibodies to EBV nuclear antigen (EBNA) detected by anticomplement immunofluorescence develop from 1 month to 6 months after infection; and, like anti-VCA, persist indefinitely6. Antibodies to EBNA indicate that the EBV infection was not recent. EBV early antigen (EA) consists of two components; diffuse (D), and restricted (R). The terms D and R reflect the different patterns of immunofluorescence staining exhibited by the two components. Antibodies to EA may appear transiently for up to three months or longer during the acute phase of IM in 85% of patients7. The antibody response to EA in IM patients is usually to the D component, whereas silent seroconversion to EBV in children may produce antibodies to the R components. A definitive diagnosis of primary EBV infection can be made with 95% of acute phase sera based on antibody titers to VCA, EBNA, and EA7.